VGI Health Technology Past Earnings Performance
Past criteria checks 0/6
VGI Health Technology's earnings have been declining at an average annual rate of -33.4%, while the Pharmaceuticals industry saw earnings growing at 31.2% annually. Revenues have been growing at an average rate of 30.3% per year.
Key information
-33.4%
Earnings growth rate
-27.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 31.2% |
| Revenue growth rate | 30.3% |
| Return on equity | n/a |
| Net Margin | -6,186.9% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How VGI Health Technology makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 0 | -2 | 1 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 2 | 0 |
| 30 Sep 22 | 0 | -2 | 2 | 0 |
| 30 Jun 22 | 0 | -2 | 2 | 0 |
| 31 Dec 21 | 0 | -2 | 1 | 0 |
| 30 Sep 21 | 0 | -2 | 2 | 0 |
| 30 Jun 21 | 0 | -3 | 2 | 0 |
| 31 Mar 21 | 0 | -3 | 2 | 0 |
| 31 Dec 20 | 0 | -2 | 2 | 0 |
| 30 Sep 20 | 0 | -2 | 2 | 0 |
| 30 Jun 20 | 0 | -1 | 1 | 0 |
| 31 Mar 20 | 0 | -1 | 1 | 0 |
| 31 Dec 19 | 0 | -1 | 1 | 0 |
| 30 Sep 19 | 0 | 1 | 1 | 0 |
| 30 Jun 19 | 0 | 3 | 1 | 0 |
| 30 Jun 16 | 0 | -21 | 8 | 0 |
| 31 Mar 16 | 0 | -23 | 9 | 0 |
| 31 Dec 15 | 5 | -27 | 12 | 0 |
| 30 Sep 15 | 6 | -23 | 11 | 0 |
| 30 Jun 15 | 2 | -19 | 10 | 0 |
| 31 Mar 15 | 4 | -18 | 12 | 0 |
| 31 Dec 14 | 6 | -16 | 14 | 0 |
| 30 Sep 14 | 7 | -15 | 13 | 0 |
| 30 Jun 14 | 8 | -13 | 12 | 0 |
| 31 Dec 13 | 6 | -7 | 5 | 0 |
| 30 Sep 13 | 6 | -6 | 4 | 0 |
| 30 Jun 13 | 6 | -5 | 4 | 0 |
| 31 Dec 12 | 4 | -7 | 2 | 0 |
| 30 Sep 12 | 3 | -5 | 2 | 0 |
Quality Earnings: VTL is currently unprofitable.
Growing Profit Margin: VTL is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: VTL is unprofitable, and losses have increased over the past 5 years at a rate of 33.4% per year.
Accelerating Growth: Unable to compare VTL's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: VTL is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-10%).
Return on Equity
High ROE: VTL's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.